H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the High-Flying Penny Stocks to Buy. On March 12, H.C. Wainwright reiterated a Buy rating on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with a $6 price target.

​The analyst noted positive post-hoc analyses of sotagliflozin, which showed cardiometabolic benefits such as reduction in HbA1c, body weight, systolic blood pressure, and insulin use. Moreover, the candidate also showed fewer hypoglycemic events after one year in type 1 diabetes patients with normal or mildly reduced kidney function.

​The firm noted that the data aligns with the ongoing STENO1 investigator-initiated trial, which gathers data on diabetic ketoacidosis incidence and could support regulatory decisions. The company plans to resubmit an NDA in 2026 for sotagliflozin as an insulin adjunct in type 1 diabetes. While the firm remains optimistic, he flagged risks such as trial failures, funding shortfalls, or dilutive financing.

​Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat human disease.

While we acknowledge the risk and potential of LXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LXRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.